ALX Oncology Holdings Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company has no approved products and generates no product revenue. Its primary assets are its pipeline, led by the CD47 blocker evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Loss | $(22.1) million | $(30.7) million | $(78.8) million | $(105.7) million |
| Net Loss Per Share | $(0.41) | $(0.58) | $(1.48) | $(2.05) |
| Research & Development Expenses | $17.4 million | $26.5 million | $59.4 million | $92.8 million |
| General & Administrative Expenses | $5.1 million | $6.1 million | $18.5 million | $19.0 million |
| Total Operating Expenses | $22.5 million | $32.6 million | $81.0 million | $111.9 million |
| Cash, Cash Equivalents & Investments | $66.5 million | $131.3 million (Dec 31, 2024) | $66.5 million | $131.3 million (Dec 31, 2024) |
| Term Loan Outstanding | $10.0 million | $10.0 million | $10.0 million | $10.0 million |
| Accumulated Deficit | $(700.0) million | $(592.0) million | $(700.0) million | $(592.0) million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 31% in Q3 2025 compared to Q3 2024. This was driven by a 34% reduction in R&D expenses and a 16% reduction in G&A expenses.
- Workforce Reduction: The decrease in personnel costs and stock-based compensation was primarily attributed to a reduction in force (RIF) completed in Q1 2025.
- Impairment Charge: The company recognized a $3.2 million non-cash impairment charge in the first nine months of 2025 related to long-lived assets (right-of-use asset and leasehold improvements) for a Palo Alto property being subleased. No impairment was recorded in the prior year period.
- Liquidity Position: Total cash, cash equivalents, and investments declined from $131.3 million at year-end 2024 to $66.5 million as of September 30, 2025, reflecting operational cash burn and investment maturities.
- Revenue: The company continues to have no product revenue.
Guidance, Outlook, and Risks
- Cash Runway: Management believes existing capital resources are sufficient to fund operations into the first quarter of 2027.
- Strategic Pivot (Gastric Cancer): Following FDA guidance that the ASPEN-06 Phase 2 data was not eligible for accelerated approval due to the availability of ENHERTU, the company will not pursue a U.S. registrational path with a Phase 3 trial in gastric cancer. They are exploring development partnerships for this indication.
- Strategic Pivot (Breast Cancer): The ASPEN-Breast study was amended to a single-arm design focusing on patients with high CD47 expression.
- Program Pause: The ASPEN-CRC study (colorectal cancer) was paused in August 2025 to streamline resources.
- ALX2004 Progress: The company dosed the first patient in the Phase 1 clinical trial for ALX2004 in August 2025.
- Nasdaq Compliance: The company received confirmation in September 2025 that it regained compliance with the Nasdaq minimum bid price requirement after a period of non-compliance earlier in the year.
- Risks: Key risks include the need for additional capital, the uncertainty of clinical trial outcomes, reliance on third-party manufacturers, and potential intellectual property disputes.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $66.5 million cash balance against the projected runway into Q1 2027, considering the paused CRC program and potential partnership delays.
- Regulatory Pathway: Confirm the specific criteria and timeline for the amended ASPEN-Breast single-arm trial and the likelihood of securing a development partner for the gastric cancer program.
- Impairment Details: Review the sublease agreement terms for the Palo Alto property to understand the impact on future facility costs and the $3.2 million impairment charge.
- Debt Covenants: Monitor compliance with the $100 million term loan facility, specifically the $25 million tranche available at lenders' discretion and any milestone requirements.
- Stock-Based Compensation: Assess the impact of the Q1 2025 workforce reduction on future stock-based compensation expenses and employee retention.